The DOI matches its Crossref record; 91 of the 92 references it cites were found in a registry or an index.
Contraceptive Hormone Use and Cardiovascular Disease
Open accessAbstract
Contraceptive hormones, most commonly prescribed as oral contraceptives (OCs), are a widely utilized method to prevent ovulation, implantation, and, therefore, pregnancy. The Women's Health Initiative demonstrated cardiovascular risk linked to menopausal hormone therapy among women without pre-existing cardiovascular disease, prompting a review of the safety, efficacy, and side effects of other forms of hormone therapy. A variety of basic science, animal, and human data suggests that contraceptive hormones have antiatheromatous effects; however, relatively less is known regarding the impact on atherosclerosis, thrombosis, vasomotion, and arrhythmogenesis. Newer generation OC formulations in use indicate no increased myocardial infarction risk for current users, but a persistent increased risk of venous thromboembolism. There are no cardiovascular data available for the newest generation contraceptive hormone formulations, including those that contain newer progestins that lower blood pressure, as well as the nonoral routes (transdermal and vaginal). Current guidelines indicate that, as with all medication, contraceptive hormones should be selected and initiated by weighing risks and benefits for the individual patient. Women 35 years and older should be assessed for cardiovascular risk factors including hypertension, smoking, diabetes, nephropathy, and other vascular diseases, including migraines, prior to use. Existing data are mixed with regard to possible protection from OCs for atherosclerosis and cardiovascular events; longer-term cardiovascular follow-up of menopausal women with regard to prior OC use, including subgroup information regarding adequacy of ovulatory cycling, the presence of hyperandrogenic conditions, and the presence of prothrombotic genetic disorders is needed to address this important issue.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although there have been no placebo-controlled trials in children, observational studies have suggested that early treatment can reduce LDL-C burden, improve endothelial function, substantially attenuate the development of atherosclerosis, and improve coronary outcomes [369-371].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [370]
Experimental — accuracy not yet measuredIn the citing paper
“Although there have been no placebo-controlled trials in children, observational studies have suggested that early treatment can reduce LDL-C burden, improve endothelial function, substantially attenuate the development of atherosclerosis, and improve coronary outcomes [369-371].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [370]
In the citing paper
“Although there have been no placebo-controlled trials in children, observational studies have suggested that early treatment can reduce LDL-C burden, improve endothelial function, substantially attenuate the development of atherosclerosis, and improve coronary outcomes [369-371].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [370]
In the citing paper
“Although there have been no placebo-controlled trials in children, observational studies have suggested that early treatment can reduce LDL-C burden, improve endothelial function, substantially attenuate the development of atherosclerosis, and improve coronary outcomes [369-371].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [370]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Protective Effects of Estrogen on the Cardiovascular System
Mendelsohn, M. E., & Karas, R. H. (1999) · New England Journal of Medicine · doi:10.1056/nejm199906103402306 · Cited by 3,119
Estrogen plus Progestin and the Risk of Coronary Heart Disease
Manson, J. E., Hsia, J., Johnson, K. C., Rossouw, J. E., Assaf, A. R., Lasser, N. L., Trevisan, M., Black, H. R., Heckbert, S. R., Detrano, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030808 · Cited by 2,065
Ehrmann, D. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041536 · Cited by 1,920
Estrogen and coronary heart disease in women
Barrett-Connor, E. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03460140089033 · Cited by 1,241
Gynecologists (2009) · Cited by 1,035
Chandra, A., Martinez, G. M., Mosher, W. D., Abma, J. C., & Jones, J. (2005) · PsycEXTRA Dataset · doi:10.1037/e414702008-001 · Cited by 957
Chen, Z., Yuhanna, I. S., Galcheva-Gargova, Z., Karas, R. H., Mendelsohn, M. E., & Shaul, P. W. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5347 · Cited by 924
Jick, H., Jick, S. S., Myers, M. W., Vasilakis‐Scaramozza, C., & Gurewich, V. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91928-7 · Cited by 721
Conjugated Equine Estrogens and Coronary Heart Disease
Hsia, J. A. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.3.357 · Cited by 607
Estrogen modulates responses of atherosclerotic coronary arteries.
Williams, J. K., Adams, M. R., & Klopfenstein, H. S. (1990) · Circulation · doi:10.1161/01.cir.81.5.1680 · Cited by 599
Coronary Heart Disease Mortality Among Young Adults in the U.S. From 1980 Through 2002
Ford, E. S., & Capewell, S. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.05.056 · Cited by 589
Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women.
Gilligan, D. M., Quyyumi, A. A., & Cannon, R. O. (1994) · Circulation · doi:10.1161/01.cir.89.6.2545 · Cited by 539
Reís, S. E., Gloth, S. T., Blumenthal, R. S., Resar, J. R., Zacur, H. A., Gerstenblith, G., & Brinker, J. A. (1994) · Circulation · doi:10.1161/01.cir.89.1.52 · Cited by 530
Menstrual cycle irregularity and risk for future cardiovascular disease
Solomon, C. G., Hu, F. B., Dunaif, A., Rich-Edwards, J. E., Stampfer, M. J., Willett, W. C., Speizer, F. E., & Manson, J. E. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.5.8471 · Cited by 528
Berek, J. S. (2019) · Cited by 477
Spinal Bone Loss and Ovulatory Disturbances
Prior, J. C., Vigna, Y. M., Schechter, M. T., & Burgess, A. E. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011013231801 · Cited by 459
Godsland, I. F., Crook, D., Simpson, R., Proudler, T., Felton, C., Lees, B., Anyaoku, V., Devenport, M., & Wynn, V. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011153232003 · Cited by 417
Drospirenone: pharmacology and pharmacokinetics of a unique progestogen
Krattenmacher, R. (2000) · Contraception · doi:10.1016/s0010-7824(00)00133-5 · Cited by 375
Pharmacological profile of progestins
Sitruk-Ware, R. L. (2004) · Maturitas · doi:10.1016/j.maturitas.2004.01.001 · Cited by 371
Drici, M., Burklow, T. R., Haridasse, V., Glazer, R. I., & Woosley, R. L. (1996) · Circulation · doi:10.1161/01.cir.94.6.1471 · Cited by 371
Oral Contraceptives and the Risk of Myocardial Infarction
Tanis, B. C., van den Bosch, M. A. A. J., Kemmeren, J. M., Cats, V. M., Helmerhorst, F. M., Algra, A., van der Graaf, Y., & Rosendaal, F. R. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa003216 · Cited by 367
Long QT Syndrome and Pregnancy
Seth, R., Moss, A. J., McNitt, S. A., Zaręba, W., Andrews, M. L., Qi, M., Robinson, J. L., Goldenberg, I., Ackerman, M. J., Benhorin, J., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.09.054 · Cited by 350
Poulter, N. R., Chang, C., Farley, T., Kelaghan, J., Meirlk, O., Marmot, M. G., Debert-Ribeiro, M., Medina, E., Artigas, J., He, S., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(97)02358-1 · Cited by 329
Prospective Study of Oral Contraceptives and Hypertension Among Women in the United States
Chasan-Taber, L., Willett, W. C., Manson, J. E., Spiegelman, D., Hunter, D. J., Curhan, G., Colditz, G. A., & Stampfer, M. J. (1996) · Circulation · doi:10.1161/01.cir.94.3.483 · Cited by 328
Croft, P., & Hannaford, P. C. (1989) · BMJ · doi:10.1136/bmj.298.6667.165 · Cited by 316
Merz, C. N. B., Johnson, B. D., Sharaf, B. L., Bittner, V., Berga, S. L., Braunstein, G. D., Hodgson, T. K., Matthews, K. A., Pepine, C. J., Reís, S. E., et al. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02763-8 · Cited by 287
(2006) · Obstetrics & Gynecology · doi:10.1097/00006250-200606000-00055 · Cited by 277
Sharaf, B. L., Pepine, C. J., Kerensky, R. A., Reís, S. E., Reichek, N., Rogers, W. J., Sopko, G. S., Kelsey, S. F., Holubkov, R., Olson, M. B., et al. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01424-2 · Cited by 274
A Prospective Study of Past Use of Oral Contraceptive Agents and Risk of Cardiovascular Diseases
Stampfer, M. J., Willett, W. C., Colditz, G. A., Speizer, F. E., & Hennekens, C. H. (1988) · New England Journal of Medicine · doi:10.1056/nejm198811173192004 · Cited by 255
Wagner, J. D., Clarkson, T. B., Clair, R. W. S., Schwenke, D. C., Shively, C. A., & Adams, M. R. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115526 · Cited by 251
Is Variant Angina the Coronary Manifestation of a Generalized Vasospastic Disorder?
Miller, D. D., Waters, D. D., Warnica, W. J., Szlachcic, J., Kreeft, J. H., & Théroux, P. (1981) · New England Journal of Medicine · doi:10.1056/nejm198103263041306 · Cited by 247
Oelkers, W., Foidart, J. M., Dombrovicz, N., Welter, A., & Heithecker, R. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.6.7775629 · Cited by 247
Combination Estrogen–Progestin Oral Contraceptives
Petitti, D. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmcp030751 · Cited by 241
Oral Contraceptives and the Risk of Myocardial Infarction
Tanis, B. C., van den Bosch, M. A. A. J., Kemmeren, J. M., Cats, V. M., Helmerhorst, F. M., Algra, A., van der Graaf, Y., & Rosendaal, F. R. (2002) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-200205000-00021 · Cited by 225
Hormone Replacement Therapy and the Cardiovascular System
Ouyang, P., Michos, E. D., & Karas, R. H. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.10.076 · Cited by 216
Contraceptivos orales y riesgo de infarto de miocardio
Tanis, B. C. (2001) · New England Journal of Medicine · Cited by 192
Oddsson, K., Leifels-Fischer, B., de Melo, N. R., Wiel-Masson, D., Benedetto, C., Verhoeven, C., & Dieben, T. O. M. (2005) · Contraception · doi:10.1016/j.contraception.2004.09.001 · Cited by 187
Dunn, N., Thorogood, M., Faragher, B. E., de Caestecker, L., MacDonald, T. M., McCollum, C. N., Thomas, S., Mann, R., & Lidegaard, Ø. (1999) · BMJ · doi:10.1136/bmj.318.7198.1579 · Cited by 169
Kurokawa, J., Tamagawa, M., Harada, N., Honda, S., Bai, C., Nakaya, H., & Furukawa, T. (2008) · The Journal of Physiology · doi:10.1113/jphysiol.2007.150367 · Cited by 148
Kitazawa, T., Hamada, E., Kitazawa, K., & Gaznabi, A. K. (1997) · The Journal of Physiology · doi:10.1113/jphysiol.1997.sp021944 · Cited by 146
Sidney, S., Petitti, D. B., Soff, G. A., Cundiff, D. L., Tolan, K., & Quesenberry, C. P. (2004) · Contraception · doi:10.1016/j.contraception.2004.02.010 · Cited by 133
Psychosocial Factors, Sex Differences, and Atherosclerosis
Kaplan, J. R., Adams, M. R., Clarkson, T. B., Manuck, S. B., Shively, C. A., & Williams, J. K. (1996) · Psychosomatic Medicine · doi:10.1097/00006842-199611000-00008 · Cited by 132
Mendelsohn, M. E., & Karas, R. H. (2007) · New England Journal of Medicine · doi:10.1056/nejme078072 · Cited by 123
Myocardial Infarction and Use of Low-Dose Oral Contraceptives
Sidney, S., Siscovick, D. S., Petitti, D. B., Schwartz, S. M., Quesenberry, C. P., Psaty, B. M., Raghunathan, T. E., Kelaghan, J. W., & Koepsell, T. D. (1998) · Circulation · doi:10.1161/01.cir.98.11.1058 · Cited by 112
Wood, A. J. J., Baird, D. T., & Glasier, A. F. (1993) · New England Journal of Medicine · doi:10.1056/nejm199305273282108 · Cited by 106
Stampfer, M. J., Willett, W. C., Colditz, G. A., Speizer, F. E., & Hennekens, C. H. (1990) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(90)90569-s · Cited by 104
Boyle, M. B., MacLusky, N. J., Naftolin, F. N., & Kaczmarek, L. K. (1987) · Nature · doi:10.1038/330373a0 · Cited by 104
Low-Dose Oral Contraceptive Use and the Risk of Myocardial Infarction
Rosenberg, L. A., Palmer, J. R., Rao, S. R., & Shapiro, S. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.8.1065 · Cited by 103
Sibai, B. M., Odlind, V., Meador, M., Shangold, G. A., Fisher, A. C., & Creasy, G. W. (2002) · Fertility and Sterility · doi:10.1016/s0015-0282(01)03264-2 · Cited by 102
Herrington, D. M., Werbel, B. L., Riley, W. A., Pusser, B. E., & Morgan, T. M. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00128-x · Cited by 95
Estrogen receptor-mediated repression of human hepatic lipase gene transcription
Jones, D. R., Schmidt, R. J., Pickard, R. T., FOXWORTHY, P. S., & Eacho, P. I. (2002) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)30144-9 · Cited by 91
A prospective study of oral contraceptive use and risk of myocardial infarction among Swedish women
Margolis, K. L., Adami, H., Luo, J., Ye, W., & Weiderpass, E. (2007) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.11.206 · Cited by 90
A Prospective Study of Oral Contraceptives and NIDDM Among U.S. Women
Chasan‐Taber, L., Willett, W. C., Stampfer, M. J., Hunter, D. J., Colditz, G. A., Spiegelman, D. L., & Manson, J. E. (1997) · Diabetes Care · doi:10.2337/diacare.20.3.330 · Cited by 88
Kaplan, J. R., Manuck, S. B., Anthony, M. S., & Clarkson, T. B. (2002) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(01)01659-3 · Cited by 85
Hormonal Contraception in Women of Older Reproductive Age
Kaunitz, A. M. (2008) · New England Journal of Medicine · doi:10.1056/nejmcp0708481 · Cited by 84
Anderson, F. D., Gibbons, W. E., & Portman, D. J. (2005) · Contraception · doi:10.1016/j.contraception.2005.09.010 · Cited by 82
Kaplan, J. R., Adams, M. R., Anthony, M. S., Morgan, T. M., Manuck, S. B., & Clarkson, T. B. (1995) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.15.12.2094 · Cited by 76
Low‐dose oral contraceptives and 24‐hour ambulatory blood pressure
Cardoso, F., Polónia, J., Santos, A., Silva‐Carvalho, J., & Ferreira‐de‐Almeida, J. (1997) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(97)00239-7 · Cited by 73 · cited 1×
“A review of 2 studies found an increase in systolic blood pressure by 7 to 8 mm Hg on average compared with systolic blood pressure in those not using OCs ( 32 ,33).”
Merz, C. N. B., Johnson, B. D., Berga, S. L., Braunstein, G. D., Reís, S. E., & Bittner, V. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.01.009 · Cited by 73
Jensen, G. B., Nyboe, J., Appleyard, M., & Schnohr, P. (1991) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a059894 · Cited by 72
Hu, P., Greendale, G. A., Palla, S. L., Reboussin, B. A., Herrington, D. M., Barrett-Connor, E. L., & Reuben, D. B. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.06.011 · Cited by 72
Cauci, S., Santolo, M. D., Culhane, J. F., Stel, G., Gonano, F., & Guaschino, S. (2008) · Obstetrics and Gynecology · doi:10.1097/aog.0b013e31816a2476 · Cited by 72
Smoking and use of oral contraceptives: Impact on thrombotic diseases
Lidegaard, Ø. (1999) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(99)70696-4 · Cited by 71
Oral Contraceptive Use and Association With Glucose, Insulin, and Diabetes in Young Adult Women
Kim, C., Siscovick, D. S., Sidney, S. S., Lewis, C. E., Kiefe, C. I., & Koepsell, T. D. (2002) · Diabetes Care · doi:10.2337/diacare.25.6.1027 · Cited by 70
Coronary atherosclerosis and myocardial infarction in young women — role of oral contraceptives
Engel, H. J., ENGEL, E., & Lichtlen, P. R. (1983) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a061365 · Cited by 70
Williams, J. K., Shively, C. A., & Clarkson, T. B. (1994) · Circulation · doi:10.1161/01.cir.90.2.983 · Cited by 69
Update on oral contraceptive pills.
Cerel-Suhl, S. L., & Yeager, B. F. (1999) · PubMed · Cited by 65
Trends in Nonfatal Coronary Heart Disease in the United States, 1980 Through 1989
DeStefano, F. (1993) · Archives of Internal Medicine · doi:10.1001/archinte.1993.00410210117013 · Cited by 64
Ambulatory blood pressure in mild hypertensive women taking oral contraceptives a case-control study
Narkiewicz, K., ROCCOGRANIERO, G., D'Este, D., Mattarei, M., Zonzin, P., & Palatini, P. (1995) · American Journal of Hypertension · doi:10.1016/0895-7061(95)96212-3 · Cited by 63
Sitruk-Ware, R. L., Ménard, J., Rad, M., Burggraaf, J., de Kam, M. L., Tokay, B. A., Sivin, I., & Kluft, C. (2007) · Contraception · doi:10.1016/j.contraception.2007.01.027 · Cited by 61
Endrikat, J., Klipping, C., Cronin, M., Gerlinger, C., Ruebig, A., Schmidt, W., & Düsterberg, B. (2002) · Contraception · doi:10.1016/s0010-7824(01)00316-x · Cited by 57
Skouby, S. O., Endrikat, J., Düsterberg, B., Schmidt, W., Gerlinger, C., Wessel, J., Goldstein, H., & Jespersen, J. (2005) · Contraception · doi:10.1016/j.contraception.2004.08.017 · Cited by 57
Cheng, J. (2006) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2005.00384.x · Cited by 56
Myocardial infarction and third generation oral contraceptives: aggregation of recent studies
Spitzer, W. O. (2002) · Human Reproduction · doi:10.1093/humrep/17.9.2307 · Cited by 49
Göl, M., Akan, P., Doğan, E., Karas, Ç. A., Saygılı, U., & Posacı, C. (2005) · Maturitas · doi:10.1016/j.maturitas.2005.05.006 · Cited by 48
Barkfeldt, J. O. A., Virkkunen, A., & Dieben, T. O. M. (2001) · Contraception · doi:10.1016/s0010-7824(01)00269-4 · Cited by 46
Snell‐Bergeon, J. K., Dabelea, D., Ogden, L. G., Hokanson, J. E., Kinney, G. L., Ehrlich, J., & Rewers, M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2025 · Cited by 45
Migraine and Angina Pectoris by Coronary Artery Spasm
Lafitte, C., EVEN, C., Henry-Lebras, F., de Toffol, B., & Autret, A. (1996) · Headache The Journal of Head and Face Pain · doi:10.1046/j.1526-4610.1996.3605332.x · Cited by 42
Oral contraceptives, lipoproteins, and atherosclerosis
Adams, M. R., Clarkson, T. B., Shively, C. A., Parks, J. S., & Kaplan, J. R. (1990) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(90)91353-e · Cited by 36
John, R., Rajasinghe, H. A., Itescu, S., Suratwalla, S., Lietz, K., Weinberg, A. D., Kocher, A. A., MANCINI, D. M., DRUSIN, R. E., Oz, M. C., et al. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)01050-0 · Cited by 35
Oral Contraceptives, Smoking and Risk of Myocardial Infarction in Young Women
Salonen, J. T. (1982) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1982.tb03186.x · Cited by 35
Dunn, N. R., Arscott, A., & Thorogood, M. (2001) · Contraception · doi:10.1016/s0010-7824(01)00172-x · Cited by 33
Suthipongse, W., & Taneepanichskul, S. (2004) · Contraception · doi:10.1016/j.contraception.2003.08.014 · Cited by 31
Mishra, R. G., Hermsmeyer, R. K., Miyagawa, K., Sarrel, P. M., Uchida, B. T., Stanczyk, F. Z., Burry, K. A., Illingworth, D. R., & Nordt, F. J. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1557 · Cited by 29
Low-dose contraceptive estrogen-progestin and coronary artery atherosclerosis of monkeys
Adams, M. R. (2000) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(00)00891-7 · Cited by 26
Hermsmeyer, R. K., Mishra, R. G., Pavčnik, D., Uchida, B. T., Axthelm, M. K., Stanczyk, F. Z., Burry, K. A., Illingworth, D. R., Kaski, J. C., & Nordt, F. J. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000126372.14332.70 · Cited by 24
Oral contraceptive use during the perimenopausal years.
Winter, J. T. V., & Bernard, M. E. (1998) · PubMed · Cited by 14
Victory, R., D'souza, C., Diamond, M. P., McNeeley, S. G., Vista-Deck, D., & Hendrix, S. L. (2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.07.135 · Cited by 13
Benefits of exogenous oestrogen in inhibiting stress-related coronary artery atherosclerosis.
Clarkson, T. B., Kaplan, Shively, C. A., & Kp, K. (1996) · PubMed · Cited by 9
Cited by
Sorted by citations
2013 ESH/ESC Guidelines for the management of arterial hypertension
Authors Task Force Members, Mancia, G., Fagard, R., Narkiewicz, K., Redon, J., Zanchetti, A., Böhm, M., Christiaens, T., Cífková, R., Backer, G. D., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,739
Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
“In contrast, alternative contraceptive measures should be recommended in women with hypercholesterolaemia [LDL-C >4 mmol/L (>160 mg/dL)] or with multiple risk factors, and in those at high-risk of thrombotic events.(391) Oestrogen replacement therapy, despite some favourable effects on lipid profiles, has not been dem…”
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Metadata
- Authors
- Shufelt, C. L., & Bairey Merz, C. N.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2009-01
- Volume
- 53
- Issue
- 3
- Pages
- 221-231
- ISSN
- 0735-1097 (ISSN-L)
- PMC
- PMC2660203
- OpenAlex
- W2128055881
- Cited by
- 287
- References
- 92
- Citations by year
- 2026: 14 · 2025: 10 · 2024: 15 · 2023: 17 · 2022: 12 · 2021: 16 · 2020: 24 · 2019: 17 · 2018: 10 · 2017: 11 · 2016: 18 · 2015: 16 · 2014: 17 · 2013: 22 · 2012: 18
- FWCI
- 3.06
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (n01hv068164-006, n01hv068162-009, n01hv068161-005, n01hv068163-006)
- National Heart, Lung, and Blood Institute (N01-HV68162, N01 HV068162, N01HV68163, N01 HV068164, N01- HV-068161, N01 HV068163)
- National Center for Research Resources (MO1-RR00425, M01RR000425)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- oral contraceptives, cardiovascular risk, hormone replacement therapy, atherosclerosis, thrombosis, venous thromboembolism, myocardial infarction, progestins, vaginal ring, cardiovascular risk assessment, Women's Health Initiative
- MeSH terms
- Adult, Age Factors, Animals, Cardiovascular Diseases, Contraceptives, Oral, Hormonal, Disease Models, Animal, Female, Humans, Middle Aged, Thromboembolism, United States, Cohort Studies, Incidence, Practice Guidelines as Topic, Premenopause, Postmenopause, Risk Assessment, Hormone Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
